Literature DB >> 29427486

Management of patients with non-alcoholic steatohepatitis (NASH) in real life.

Lawrence Serfaty1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is a prevalent condition that is associated with the development of cirrhosis and hepatocellular carcinoma and with no approved treatment options except for lifestyle changes. Guidelines have been drafted for the management of NAFLD patients in this setting. Because of the lack of real-life cohort data, we will focus on practice surveys on the management of patients with NAFLD/NASH, which included primary care practitioners, gastroenterologists/hepatologists and other specialists from various countries. Practice patterns have been collected from interviews with practitioners or reviews of patient's files. This review discusses the screening, diagnosis and therapeutic management of NAFLD/NASH patients in real life practice, as well as adherence to guidelines.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chart review; diagnosis; monitoring; practice survey; screening; therapeutic management

Mesh:

Year:  2018        PMID: 29427486     DOI: 10.1111/liv.13637

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  11 in total

1.  Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis.

Authors:  Iris Y Zhou; Veronica Clavijo Jordan; Nicholas J Rotile; Eman Akam; Smitha Krishnan; Gunisha Arora; Hema Krishnan; Hannah Slattery; Noah Warner; Nathaniel Mercaldo; Christian T Farrar; Jeremy Wellen; Robert Martinez; Franklin Schlerman; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan
Journal:  Radiology       Date:  2020-04-28       Impact factor: 11.105

2.  The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.

Authors:  Wolf Peter Hofmann; Peter Buggisch; Lisa Schubert; Nektarios Dikopoulos; Jeannette Schwenzer; Marion Muche; Gisela Felten; Renate Heyne; Patrick Ingiliz; Anna Schmidt; Kerstin Stein; Heiner Wedemeyer; Thomas Berg; Johannes Wiegand; Frank Lammert; Stefan Zeuzem; Jörn M Schattenberg
Journal:  JHEP Rep       Date:  2020-08-04

3.  Spontaneous Development of Hepatocellular Carcinoma and B-Cell Lymphoma in Mosaic and Heterozygous Brca2 and Cdkn1a Interacting Protein Knockout Mice.

Authors:  Huimei Lu; Caiyong Ye; Xing Feng; Jingmei Liu; Mantu Bhaumik; Bing Xia; Chen Liu; Zhiyuan Shen
Journal:  Am J Pathol       Date:  2020-03-20       Impact factor: 4.307

4.  Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes.

Authors:  Juan He; Jian Ding; Qiuhua Lai; Xinke Wang; Aimin Li; Side Liu
Journal:  Front Physiol       Date:  2019-05-29       Impact factor: 4.566

5.  Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis.

Authors:  Munkhzul Ganbold; Yohei Owada; Yusuke Ozawa; Yasuhiro Shimamoto; Farhana Ferdousi; Kenichi Tominaga; Yun-Wen Zheng; Nobuhiro Ohkohchi; Hiroko Isoda
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

6.  Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study.

Authors:  Jeong-Ju Yoo; Yang Jae Yoo; Woo Ram Moon; Seung Up Kim; Soung Won Jeong; Ha Na Park; Min Gyu Park; Jae Young Jang; Su Yeon Park; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Sang Gyune Kim; Young Seok Kim; Ji Hoon Kim; Jong Eun Yeon; Kwan Soo Byun
Journal:  Korean J Intern Med       Date:  2019-11-08       Impact factor: 2.884

7.  A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease.

Authors:  Fredrik Åberg; Christopher J Danford; Maja Thiele; Mats Talbäck; Ditlev Nytoft Rasmussen; Z Gordon Jiang; Niklas Hammar; Patrik Nasr; Mattias Ekstedt; Anna But; Pauli Puukka; Aleksander Krag; Jouko Sundvall; Iris Erlund; Veikko Salomaa; Per Stål; Stergios Kechagias; Rolf Hultcrantz; Michelle Lai; Nezam Afdhal; Antti Jula; Satu Männistö; Annamari Lundqvist; Markus Perola; Martti Färkkilä; Hannes Hagström
Journal:  Hepatol Commun       Date:  2021-03-08

8.  Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model.

Authors:  Jesús Funuyet-Salas; Agustín Martín-Rodríguez; María Ángeles Pérez-San-Gregorio; Manuel Romero-Gómez
Journal:  J Clin Med       Date:  2021-05-20       Impact factor: 4.241

9.  Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease.

Authors:  Jesús Funuyet-Salas; María Ángeles Pérez-San-Gregorio; Agustín Martín-Rodríguez; Manuel Romero-Gómez
Journal:  Front Med (Lausanne)       Date:  2020-10-22

10.  Quality of Life and Coping in Nonalcoholic Fatty Liver Disease: Influence of Diabetes and Obesity.

Authors:  Jesús Funuyet-Salas; María Ángeles Pérez-San-Gregorio; Agustín Martín-Rodríguez; Manuel Romero-Gómez
Journal:  Int J Environ Res Public Health       Date:  2021-03-28       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.